Works matching IS 10781552 AND DT 2018 AND VI 24 AND IP 6
Results: 11
A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 453, doi. 10.1177/1078155217713363
- By:
- Publication type:
- Article
Retraction notice.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. NP1, doi. 10.1177/1078155218790179
- Publication type:
- Article
A response to the letter to the editor on “Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study”.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 478, doi. 10.1177/1078155218782614
- By:
- Publication type:
- Article
Does resolved HBV or anti-HBc-only carry the same risk of HBV reactivation?
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 477, doi. 10.1177/1078155218782593
- By:
- Publication type:
- Article
RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer – real world claim data.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 424, doi. 10.1177/1078155217719585
- By:
- Publication type:
- Article
Do checkpoint inhibitors rely on gut microbiota to fight cancer?
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 468, doi. 10.1177/1078155217715903
- By:
- Publication type:
- Article
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 412, doi. 10.1177/1078155217714859
- By:
- Publication type:
- Article
BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 433, doi. 10.1177/1078155217710553
- By:
- Publication type:
- Article
Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 403, doi. 10.1177/1078155217707335
- By:
- Publication type:
- Article
How can we ensure value for money from expenditure on injectable cancer drugs?
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 473, doi. 10.1177/1078155217706195
- By:
- Publication type:
- Article